Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neoadjuvant chemoradiotherapy in rectal cancer

被引：1
|
作者：
Niels W. Schurink
Simon R. van Kranen
Maaike Berbee
Wouter van Elmpt
Frans C. H. Bakers
Sander Roberti
Joost J. M. van Griethuysen
Lisa A. Min
Max J. Lahaye
Monique Maas
Geerard L. Beets
Regina G. H. Beets-Tan
Doenja M. J. Lambregts
机构：
[1] The Netherlands Cancer Institute,Department of Radiology
[2] University of Maastricht,GROW School for Oncology and Developmental Biology
[3] The Netherlands Cancer Institute,Department of Radiation Oncology
[4] Maastricht University Medical Centre,Department of Radiation Oncology (MAASTRO Clinic)
[5] Maastricht University Medical Center+,Department of Radiology
[6] The Netherlands Cancer Institute,Department of Epidemiology and Biostatistics
[7] The Netherlands Cancer Institute,Department of Surgery
来源：
European Radiology | 2021年 / 31卷
关键词：
Rectal neoplasms; Chemoradiotherapy; Positron-emission tomography computed tomography; Magnetic resonance imaging; Logistic models;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：7031 / 7038
页数：7
相关论文
共 50 条
  • [21] The role of MRI and 18F-FDG PET/CT with respect to evaluation of pathological response in the rectal cancer patients after neoadjuvant chemoradiotherapy
    Avci, Gulhan Guler
    Aral, Ipek Pinar
    INDIAN JOURNAL OF CANCER, 2023, 60 (01) : 52 - 58
  • [22] FDG-PET/CT in patients with locally advanced rectal cancer undergoing neoadjuvant therapy
    Travaini, L. L.
    Leonardi, C.
    Elisei, F.
    Zampino, G.
    Iodice, S.
    Trifiro, G.
    Ferrari, M.
    Mei, R.
    Orecchia, R.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S338 - S338
  • [23] FDG-PET/CT in the Evaluation of Patients with Suspected Local Recurrence of Rectal Cancer
    Peiro Valganon, V.
    Garcia Vicente, A. M.
    Pilkington Woll, J. P.
    Villa Guzman, J. C.
    Talavera Rubio, M. P.
    Bellon Garcia, M. E.
    Palomar Munoz, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S241 - S241
  • [24] Molecular Imaging (FDG-PET/CT) Response to Neoadjuvant Oxaliplatin and Chemoradiation in Rectal Cancer as Prognostic Factor in Surveillance
    De La Mata, M.
    Calvo, F.
    Gomez Espi, M.
    Carreras, J.
    Alvarez, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S339 - S339
  • [25] Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?
    Deantonio, Letizia
    Caroli, Angela
    Puta, Erinda
    Ferrante, Daniela
    Apicella, Francesco
    Turri, Lucia
    Sacchetti, Gianmauro
    Brambilla, Marco
    Krengli, Marco
    RADIATION ONCOLOGY, 2018, 13
  • [26] Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?
    Letizia Deantonio
    Angela Caroli
    Erinda Puta
    Daniela Ferrante
    Francesco Apicella
    Lucia Turri
    Gianmauro Sacchetti
    Marco Brambilla
    Marco Krengli
    Radiation Oncology, 13
  • [27] Importance of FDG-PET/CT for surgery of rectal cancer
    Wiegering, A.
    Herrmann, K.
    Bluemel, C.
    Buck, A. K.
    Germer, C. -T.
    CHIRURG, 2014, 85 (06): : 487 - 492
  • [28] FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients
    Soubra, Ayman
    Gencturk, Mehmet
    Froelich, Jerry
    Balaji, Priya
    Gupta, Shilpa
    Jha, Gautam
    Konety, Badrinath R.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (05) : 360 - 364
  • [29] FDG-PET/CT in predicting aggressiveness of rectal cancer
    Ahmed, Iman Sherif
    El Gaafary, Saher Mohamed
    Elia, Remon Zaher
    Hussein, Rasha S.
    EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2021, 52 (01):
  • [30] FDG-PET/CT in predicting aggressiveness of rectal cancer
    Iman Sherif Ahmed
    Saher Mohamed El Gaafary
    Remon Zaher Elia
    Rasha S. Hussein
    Egyptian Journal of Radiology and Nuclear Medicine, 52
12345